Exophthalmos clinical trials
The registry lists 20 studies for Exophthalmos across more than 10 countries. 4 are recruiting or about to start. 1 of them are mainly about Exophthalmos (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-26. Counting its 2 narrower conditions too, such as Graves Ophthalmopathy: 328 studies, 105 open.
Get an email when these change. Save the Exophthalmos studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Amgen (3) · Sling Therapeutics, Inc. (2) · Hospital Universitario 12 de Octubre (1) · Haukeland University Hospital (1) · University of Zurich (1) · Rebecca Bahn (1) · University of North Carolina, Chapel Hill (1) · Ethyreal Bio, Inc. (1)
What is being tested here
Drugs under test in Exophthalmos studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 4 Exophthalmos studies recruiting now, 3 (75%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 4 (100%) | 4 (100%) |
| 85 | 3 (75%) | 3 (75%) |
Across all 20 studies, recruiting or not: 5% stop at 75 or younger and 5% at 65; 5% take children; 0% are for women only and 0% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye DiseaseRecruitingNCT07885605Phase 11 country
- Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the EyeRecruitingNCT076349131 country
- Sirolimus vs Corticosteroids in Treatment of Thyroid Eye DiseaseRecruitingNCT04936854Phase 21 country
- Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)RecruitingNCT06112340Phase 2/31 country
- A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)CompletedNCT05276063Phase 2/35 countries
- A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye DiseaseActive, not recruitingNCT06088979Phase 211 countries
- A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)TerminatedNCT04737330Phase 31 country
- A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye DiseaseCompletedNCT06226545Phase 23 countries
- Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical StudyCompletedNCT03298867Phase 33 countries
- A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseaseCompletedNCT04583735Phase 41 country
- Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye DiseaseApproved for marketingNCT040408941 country
- Antithymocyte Globulin as a Second Line Therapy in Graves OrbitopathyStatus unknownNCT05199103Not applicable1 country
- Exophthalmometry With 3D Face ScannersStatus unknownNCT04704414Not applicable1 country
- Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves OrbitopathyCompletedNCT03278964Not applicable1 country
- Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related OrbitopathyCompletedNCT04025034Not applicable
- Trial of Rituximab for Graves' OphthalmopathyCompletedNCT00595335Phase 2/31 country
- The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse ReactionsStatus unknownNCT01204359Phase 31 country
- Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's OrbitopathyStatus unknownNCT01999790Not applicable1 country
- Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune TreatmentTerminatedNCT01893450Not applicable1 country
- Reliability of Hertel Exophthalmometer MeasurementsCompletedNCT016911831 country